These findings not only enhance our understanding of the tumor-promoting role of sVASN to accelerate tumor malignant progression but also highlight the sVASN-CD71-STAT3 axis as a promising therapeutic strategy for future clinical applications. Here, TFRC is linked to neoplasm.